Braun Stacey Associates Inc. Has $1.27 Million Stock Holdings in Amgen Inc. $AMGN

Braun Stacey Associates Inc. reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 88.6% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,500 shares of the medical research company’s stock after selling 34,949 shares during the quarter. Braun Stacey Associates Inc.’s holdings in Amgen were worth $1,270,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in Amgen by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company’s stock valued at $14,996,807,000 after buying an additional 841,117 shares during the period. State Street Corp boosted its position in shares of Amgen by 0.6% during the 2nd quarter. State Street Corp now owns 29,357,026 shares of the medical research company’s stock worth $8,196,775,000 after acquiring an additional 177,035 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Amgen by 2.3% during the 2nd quarter. Geode Capital Management LLC now owns 13,018,617 shares of the medical research company’s stock worth $3,619,489,000 after acquiring an additional 291,271 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Amgen by 5.6% in the second quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock valued at $3,600,043,000 after acquiring an additional 687,735 shares during the last quarter. Finally, Laurel Wealth Advisors LLC raised its position in Amgen by 27,765.8% during the second quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock valued at $1,870,880,000 after purchasing an additional 6,676,575 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling

In related news, EVP Murdo Gordon sold 6,879 shares of the stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the sale, the executive vice president directly owned 41,923 shares in the company, valued at $14,120,924.09. This represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Nancy A. Grygiel sold 3,139 shares of the firm’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the transaction, the senior vice president directly owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. This represents a 30.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 10,908 shares of company stock valued at $3,674,966 over the last 90 days. 0.76% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Wall Street Zen raised Amgen from a “buy” rating to a “strong-buy” rating in a report on Monday, December 15th. The Goldman Sachs Group restated a “buy” rating on shares of Amgen in a research report on Tuesday, November 25th. Daiwa Capital Markets boosted their target price on Amgen from $310.00 to $370.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 18th. DZ Bank increased their target price on shares of Amgen from $335.00 to $364.00 in a report on Monday, November 10th. Finally, Morgan Stanley reduced their price target on shares of Amgen from $329.00 to $304.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Amgen currently has a consensus rating of “Moderate Buy” and an average price target of $335.35.

Amgen Stock Performance

NASDAQ:AMGN opened at $327.31 on Friday. The stock’s 50-day moving average is $325.36 and its 200-day moving average is $302.57. Amgen Inc. has a 1-year low of $257.05 and a 1-year high of $346.38. The company has a current ratio of 1.28, a quick ratio of 0.99 and a debt-to-equity ratio of 5.45. The stock has a market cap of $176.25 billion, a P/E ratio of 25.29, a price-to-earnings-growth ratio of 3.04 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The business had revenue of $9.56 billion during the quarter, compared to analyst estimates of $8.98 billion. During the same quarter last year, the business earned $5.58 EPS. The firm’s quarterly revenue was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Equities research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.1%. This is a boost from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is presently 73.57%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.